<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143465</url>
  </required_header>
  <id_info>
    <org_study_id>H-15019063</org_study_id>
    <nct_id>NCT03143465</nct_id>
  </id_info>
  <brief_title>Pharmacologically Triggered Migraine Without Aura and Neuroimaging</brief_title>
  <official_title>MR-Angiografi (MRA) og MR-Spektroskopi (MRS) Hos Raske forsøgspersoner og Patienter Med migræne Uden Aura Provokeret Med Calcitonin Gen-relateret Peptid (CGRP) og Sildenafil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is a highly disabling disorder affecting 14% of the general population Worldwide and
      ranked as the 6th most debilitating disease worldwide by the WHO. One of the most fundamental
      questions of migraine, which remains to be elucidated, is the mechanism behind the generation
      of migraine attacks.

      The investigators will use calcitonin gene-related peptide (CGRP) and sildenafil as
      pharmacological triggers of migraine, combined with advanced neuroimaging techniques, to
      investigate the attack initiating pathophysiology.

      Both substances have previously been administered to healthy participants and migraine
      without aura patients, inducing headache and migraine-like-attacks.

      The investigators hope to contribute with novelty to the current understanding of the
      migraine pathophysiology and development of more efficient treatment of migraine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CGRP and sildenafil induced headache and MRI changes</measure>
    <time_frame>0- 12h</time_frame>
    <description>CGRP and sildenafil induced headache and MRI changes</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Migraine With Aura</condition>
  <arm_group>
    <arm_group_label>CGRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin Gene-Related Peptide</intervention_name>
    <arm_group_label>CGRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 50 years

          -  Weight: 50-100 kg

          -  Diagnosis of migraine without aura (patient group only)

          -  Attacks of migraine without aura at least once every second month (patient group only)

        Exclusion Criteria:

          -  Inconsistent laterality of headache

          -  History or family history of migraine (healthy subject group only)

          -  Tension-type headache more than one day per month on average (healthy subject group
             only)

          -  Tension-type headache to such a degree that the episodic migraine diagnosis is no
             longer fulfilled

          -  Any other primary headache disorder

          -  Daily intake of medication (apart from oral contraceptives)

          -  Intake of any medication less than 4 half-lives before study start

          -  Daily smoking

          -  Pregnant or breastfeeding women

          -  Headache 48 h prior to study day

          -  Hypertension on the study day (systolic BP&gt;150 mmHg or diastolic BP&gt; 100 mmHg)

          -  Hypotension on the study day (systolic BP&lt;90 mmHg or diastolic BP&lt;50 mmHg)

          -  History of any cardiovascular disease including cerebrovascular disease

          -  Any disorder, that is deemed ineligible for participation by the study physicians

          -  Contraindications of MRI

          -  No use of safe contraception (women of fertile age only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center, University Hospital</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Samaira Younis</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Katacalcin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

